Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 62(1), 10–29 (2012).
   PubMed Web of Science ®Google Scholar
• Linehan WM, Pinto PA, Srinivasan R et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res. 13(2 Pt 2), 671s–679s (2007).
   PubMed Web of Science ®Google Scholar
• Linehan WM, Bratslavsky G, Pinto PA et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 61, 329–343 (2010).
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883–892 (2012).
   PubMed Web of Science ®Google Scholar
• Xu X, Hou Y, Yin X et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148(5), 886–895 (2012).
   PubMed Web of Science ®Google Scholar
• Henske EP. The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked? Curr. Mol. Med. 4(8), 825–831 (2004).
   PubMedGoogle Scholar
• Maher ER. Von Hippel–Lindau disease. Curr. Mol. Med. 4(8), 833–842 (2004).
   PubMed Web of Science ®Google Scholar
• Cook JD, Walker CL. The Eker rat: establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma. Curr. Mol. Med. 4(8), 813–824 (2004).
   PubMed Web of Science ®Google Scholar
• Yeung RS. Lessons from the Eker rat model: from cage to bedside. Curr. Mol. Med. 4(8), 799–806 (2004).
   PubMedGoogle Scholar
• Linehan WM, Pinto PA, Bratslavsky G et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 115(Suppl. 10), 2252–2261 (2009).
   PubMedGoogle Scholar
• Milella M, Felici A. Biology of metastatic renal cell carcinoma. J. Cancer 2, 369–373 (2011).
   PubMed Web of Science ®Google Scholar
• Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr. Opin. Oncol. 24(3), 284–290 (2012).
   PubMed Web of Science ®Google Scholar
• Posadas EM, Figlin RA. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology 26(3), 290–301 (2012).
   PubMedGoogle Scholar
• Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol. Oncol. Clin. North Am. 25(4), 835–852 (2011).
   PubMed Web of Science ®Google Scholar
• Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 71(9), 1179–1191 (2011).
   PubMed Web of Science ®Google Scholar
• Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 16(Suppl. 2), 45–50 (2011).
   PubMed Web of Science ®Google Scholar
• Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl. 2), 14–22 (2011).
   PubMed Web of Science ®Google Scholar
• Harshman LC, Xie W, Bjarnason GA et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 13(9), 927–935 (2012).
   PubMed Web of Science ®Google Scholar
• Manola J, Royston P, Elson P et al.; International Kidney Cancer Working Group. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin. Cancer Res. 17(16), 5443–5450 (2011).
   PubMed Web of Science ®Google Scholar
• Powles T, Hutson TE. Difficulty in predicting survival in metastatic renal cancer. Lancet Oncol. 13(9), 859–860 (2012).
   PubMedGoogle Scholar
• Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br. J. Cancer 104(3), 399–406 (2011).
   PubMed Web of Science ®Google Scholar
• Haddad H, Rini BI. Current treatment considerations in metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 13(2), 212–229 (2012).
   PubMed Web of Science ®Google Scholar
• Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(Suppl. 2), 32–44 (2011).
   PubMed Web of Science ®Google Scholar
• Eisen T, Sternberg CN, Robert C et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J. Natl. Cancer Inst. 104(2), 93–113 (2012).
   PubMed Web of Science ®Google Scholar
• Patard JJ, Porta C, Wagstaff J, Gschwend JE. Optimizing treatment for metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 11(12), 1901–1911 (2011).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. 107(8), 1190–1199 (2011).
   PubMed Web of Science ®Google Scholar
• Zustovich F, Lombardi G, Farina P. Treating patients with metastatic renal carcinoma: an escape from Phase III. Expert Rev. Anticancer Ther. 12(7), 919–927 (2012).
   PubMed Web of Science ®Google Scholar
• Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit. Rev. Oncol. Hematol. 82(3), 323–337 (2012).
   PubMed Web of Science ®Google Scholar
• Santos N, Wenger JB, Havre P et al. Combination therapy for renal cell cancer: what are possible options? Oncology 81(3–4), 220–229 (2011).
   PubMedGoogle Scholar
• Escudier B, Negrier S, Gravis G et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA Phase II trial. J. Clin. Oncol. 28(Suppl. 15), Abstract 4516 (2010).
   Google Scholar
• Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer A, Escudier B. Randomized Phase IIIB trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT. Ann. Oncol. Suppl(Proc ESMO), Abstract LBA21 (2012).
   Google Scholar
• Ravaud A, Barrios CH, Anak O et al. Randomized Phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferon alfa-2a (IFN) + BEV in patients (pts) with metastatic renal cell carcinoma (mRCC): RECORD-2. Ann. Oncol. Suppl(Proc. ESMO), Abstract 783 (2012).
   PubMedGoogle Scholar
• Porta C, Paglino C. Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma. Oncol. Rev. 4, 1–3 (2010).
   Google Scholar
• Sonpavde G, Choueiri TK, Escudier B et al. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur. Urol. 61(2), 307–316 (2012).
   PubMed Web of Science ®Google Scholar
• Procopio G, Verzoni E, Iacovelli R, Guadalupi V, Gelsomino F, Buzzoni R. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev. Anticancer Ther. 11(11), 1631–1640 (2011).
   PubMed Web of Science ®Google Scholar
• Porta C, Tortora G, Linassier C et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med. Oncol. 29(3), 1896–1907 (2012).
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat. Rev. Clin. Oncol. 9(6), 327–337 (2012).
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. Eur. J. Med. Clin. Oncol. 2, 67–72 (2011).
   Google Scholar
• Calvo E, Ravaud A, Bellmunt J. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFR–TKI? Cancer Treat. Rev. doi:10.1016/j.ctrv.2012.06.010 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat. Rev. 38(8), 981–987 (2012).
   PubMed Web of Science ®Google Scholar
• Larriba JL, Espinosa E, Carbonero IG et al. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 31(Suppl. 1), 11–17 (2012).
   Google Scholar
• Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev. Anticancer Ther. 11(4), 639–649 (2011).
   PubMed Web of Science ®Google Scholar
• Park K, Lee JL, Park I et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med. Oncol. 29(5), 3291-3297 (2012).
   Google Scholar
• Motzer RJ, Escudier B, Oudard S et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al.; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18), 4256–4265 (2010).
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378(9807), 1931–1939 (2011).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P et al. Axitinib vs sorafenib for advanced renal cell carcinoma: Phase III overall survival results and analysis of prognostic factors. Ann. Oncol. Suppl(Proc. ESMO), Abstract 793 (2012).
   PubMedGoogle Scholar
• Hutson TE, Escudier B, Esteban E et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial. Ann. Oncol. Suppl(Proc. ESMO), Abstract LBA22 (2012).
   Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26(22), 3743–3748 (2008).
   PubMed Web of Science ®Google Scholar
• Bracarda S, Bellmunt J, Melichar B et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the Phase III AVOREN trial. BJU Int. 107(2), 214–219 (2011).
   PubMed Web of Science ®Google Scholar
• Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48–62 (2011).
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 27(27), 4462–4468 (2009).
   PubMed Web of Science ®Google Scholar
• Sarker D, Molife R, Evans TR et al. A Phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 14(7), 2075–2081 (2008).
   PubMed Web of Science ®Google Scholar
• Angevin E, Grunwald V, Ravaud A et al. A Phase II study of Dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J. Clin. Oncol. 29(Suppl.), Abstract 4551 (2011).
   Google Scholar
• Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10(12), 2298–2308 (2011).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Pal SK, McDermott DF et al. Efficacy of Cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J. Clin. Oncol. 30(Suppl.), Abstract 4504 (2012).
   Google Scholar
• Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A Phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115(11), 2438–2446 (2009).
   PubMed Web of Science ®Google Scholar
• Mackenzie MJ, Rini BI, Elson P et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann. Oncol. 22(1), 145–148 (2011).
   PubMed Web of Science ®Google Scholar
• Milella M, Di Lorenzo G, Felici A et al. Medical optimization of Torisel® (motor): a Phase II trial of temsirolimus as second-line treatment for advanced RCC by the Italian Kidney Cancer Group (GIR). Ann. Oncol. Suppl(Proc. ESMO), Abstract 846 (2012).
   Google Scholar
• Richter S, Pfister SD, Thuer D et al. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 31(Suppl.), 234–236 (2008).
   Google Scholar
• Gerullis H, Bergmann L, Maute L et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med. Oncol. 27(2), 373–378 (2010).
   PubMed Web of Science ®Google Scholar
• Lamm W, Vogl UM, Bojic M et al. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. Acta Oncol. 51(1), 101–106 (2012).
   PubMed Web of Science ®Google Scholar
• Heng DY, Mackenzie MJ, Vaishampayan UN et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549–1555 (2012).
   PubMed Web of Science ®Google Scholar
• Albiges L, Iacovelli R, Porta C et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib – is there any active treatment? Proc. (ECCO/ESMO), Abstract 7143 (2011).
   Google Scholar
• Elaidi RT, Beuselinck B, Maj-HES A et al. What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI–TKI or TKI–mTORi? A European retrospective study. J. Clin. Oncol. 30(Suppl. 5), Abstract 375 (2012).
   Google Scholar
• Al-Marrawi MY, Rini BI, Harshman LC et al. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (pts). J. Clin. Oncol. 29(Suppl.), Abstract 4555 (2011).
   Google Scholar
• Iacovelli R, Santoni M, Di Lorenzo G et al. Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (tts) for metastatic renal-cell carcinoma (mRCC). Ann. Oncol. (Suppl. Proc ESMO), Abstract 818 (2012).
   Google Scholar
• Vickers MM, Choueiri TK, Rogers M et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 76(2), 430–434 (2010).
   PubMed Web of Science ®Google Scholar
• Heng DY, Lee JL, Harshman LC et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 30(Suppl. 5), Abstract 387 (2012).
   Google Scholar
• Rini BI. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin. Cancer Res. 16(5), 1348–1354 (2010).
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 10(10), 992–1000 (2009).
   PubMed Web of Science ®Google Scholar
• Schor-Bardach R, Alsop DC, Pedrosa I et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251(3), 731–742 (2009).
   PubMedGoogle Scholar
• Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70(3), 1063–1071 (2010).
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4), 299–309 (2005).
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Jo WS, Duerr EM et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat. Med. 11(9), 992–997 (2005).
   PubMed Web of Science ®Google Scholar
• Fischer C, Jonckx B, Mazzone M et al. Anti-PlGF inhibits growth of VEGFR-inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3), 463–475 (2007).
   PubMed Web of Science ®Google Scholar
• Fernando NT, Koch M, Rothrock C et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin. Cancer Res. 14(5), 1529–1539 (2008).
   PubMed Web of Science ®Google Scholar
• Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23(5), 537–548 (2009).
   PubMed Web of Science ®Google Scholar
• Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci. STKE 2006(346), re7 (2006).
   PubMedGoogle Scholar
• Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest. 116(7), 1767–1775 (2006).
   PubMed Web of Science ®Google Scholar
• Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. (Lond.) 574(Pt 1), 63–71 (2006).
   Google Scholar
• Edinger AL, Thompson CB. An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 23(33), 5654–5663 (2004).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Buonerba C, Federico P et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur. Urol. 58(6), 906–911 (2010).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Cartenì G, Autorino R et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J. Clin. Oncol. 27(27), 4469–4474 (2009).
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220–231 (2009).
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6(9), 734–745 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(8), 1280–1289 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Agarwal N, Beard C et al.; National Comprehensive Cancer Network. Testicular cancer. J. Natl. Compr. Canc. Netw. 10(4), 502–535 (2012).
   PubMed Web of Science ®Google Scholar
• Rini BI, Garcia J, Elson P et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J. Urol. 187(5), 1548–1554 (2012).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P et al.; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367(2), 107–114 (2012).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
   PubMed Web of Science ®Google Scholar
• Ciuffreda L, Del Bufalo D, Desideri M et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11(8), 720–731 (2009).
   PubMedGoogle Scholar
• Tran HT, Liu Y, Zurita AJ et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of Phase 2 and Phase 3 trials. Lancet Oncol. 13(8), 827–837 (2012).
   PubMed Web of Science ®Google Scholar
• Bottos A, Martini M, Di Nicolantonio F et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc. Natl Acad. Sci. USA 109(6), E353–E359 (2012).
   PubMed Web of Science ®Google Scholar
• McDermott DF. Immunotherapy and targeted therapy combinations in renal cancer. Curr. Clin. Pharmacol. 6(3), 207–213 (2011).
   PubMedGoogle Scholar
• Bracarda S, Porta C, Boni C et al. Could interferon still play a role in metastatic renal cell carcinoma? a randomized study of two schedules of sorafenib plus interferon-α 2a (RAPSODY). Eur. Urol. (2012) (In Press).
   Google Scholar
• Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Ribas A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366(26), 2517–2519 (2012).
   PubMed Web of Science ®Google Scholar